In a seminal article translating the findings from the proline metabolic axis to studies of patients with breast cancer, Ding et al. analyzed PYCRs and compared PYCR1 with PYCR2 in 139 new patients as well as data from 2353 assessable breast cancer cases (17). This evidence concerns the gene PYCR2 and breast cancer.